Ono Pharmaceutical Co. (OTCMKTS:OPHLF – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $15.5580, but opened at $14.45. Ono Pharmaceutical shares last traded at $14.45, with a volume of 459 shares traded.
Analyst Ratings Changes
Separately, Zacks Research raised shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, Ono Pharmaceutical currently has an average rating of “Strong Buy”.
Get Our Latest Research Report on Ono Pharmaceutical
Ono Pharmaceutical Stock Performance
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.
One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.
Recommended Stories
- Five stocks we like better than Ono Pharmaceutical
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
- Trump Accounts: Comparing the 5 Selected Low-Cost Index ETFs
- Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
